U.S. pharma large copyright scrapped two experimental weight loss capsules last 12 months—a after-every day pill, lotiglipron, because of elevated liver enzymes and a twice-everyday tablet, danuglipron, because of sturdy Uncomfortable side effects—but CEO Albert Bourla has mentioned the company is set to “Engage in and gain” from the weight